Last updated on May 2017

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Cancer


Brief description of study

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Cancer

Detailed Study Description

The MR-guided ExAblate Focused Ultrasound study is being conducted to assess the safety and effectiveness of an investigational device for the treatment of prostate cancer.

The ExAblate treatment is a focal treatment where a small portion of the prostate is treated, only where the cancer is located.

The study will enroll 100 patients with intermediate risk, localized, organ confined prostate cancer. For most study patients, this study will last for up to 26 – 30 months. If you qualify for the study, you will receive the ExAblate treatment.

This clinical research study will evaluate the safety and effectiveness of ExAblate for the treatment of intermediate risk, localized, organ confined prostate cancer.

Clinical Study Identifier: TX149745

Find a site near you

Start Over

Brigham & Women's Hospital

Located in: Boston, MA USA
5.21miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.